title: [Combined irinotecan (CPT-11) and nedaplatin (254-S) therapy for advanced and/or recurrent cervical cancer].
abstract: We performed combination therapy with irinotecan (CPT-11) plus nedaplatin (254-S) for patients with cervical cancer. A total of 9 patients with cervical cancer (5 patients treated in neoadjuvant setting and 4 patients for recurrent disease) were administered 80 mg/m(2) of 254-Sintravenously on day 1 and 50 mg/m(2) of CPT-11 intravenously on day 1, 8 and 15. Treatment was repeated every 4 weeks. The average number of courses administered was 3.8 (range, 2-6). Grade 3 or 4 adverse events were leukopenia in 4 patients, thrombocytopenia in 1 patient and vomiting in 1 patient. The response rate was 40% in the neoadjuvant setting (2 PRs) and 75% in recurrent disease (3 PRs).
authors.affiliation: Department of Obstetrics and Gynecology, Atsugi Civilian Hospital.
authors.forename: Rieko
authors.initials: R
authors.lastname: Hiruma
authors.forename: Taizan
authors.initials: T
authors.lastname: Kamide
authors.forename: Noriaki
authors.initials: N
authors.lastname: Anzai
authors.forename: Ryuma
authors.initials: R
authors.lastname: Matsumoto
authors.forename: Yuzuru
authors.initials: Y
authors.lastname: Kotake
authors.forename: Toshiki
authors.initials: T
authors.lastname: Wachi
authors.forename: Hideo
authors.initials: H
authors.lastname: Shinozaki
authors.forename: Akio
authors.initials: A
authors.lastname: Tada
authors.forename: Naoki
authors.initials: N
authors.lastname: Kamiya
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sasaki
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D014057:Tomography, X-Ray Computed; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D014408:Biomarkers, Tumor; D009944:Organoplatinum Compounds; D000077146:Irinotecan; C053989:nedaplatin; D002166:Camptothecin